MedTrace Logo

Study of Thymopentin in Patients After Curative Resection of Small Hepatocellular Carcinoma

NCT00460681 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2007-10-31

No results posted yet for this study

Summary

The purpose of this study is to evaluate the clinical efficacy of thymopentin on the prevention of the recurrence and metastasis of small HCC after resection.

Conditions

Interventions

DRUG

Thymopentin

subcutaneously or intramuscular inject at the dosage of 10 mg every second day (twice a week) for consecutive 3 months.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Jia Fan, MD · Liver Cancer Institute and Zhongshan Hospital, Fudan University, 200032, Shanghai, China.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Completion
2012-02-29

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00460681 on ClinicalTrials.gov